Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape. Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively. Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Post-Traumatic Stress Disorder (PTSD) - Overview Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development Addex Therapeutics Ltd Amorsa Therapeutics Inc Azevan Pharmaceuticals Inc Bionomics Ltd Catalyst Pharmaceuticals Inc Cerecor Inc Chronos Therapeutics Ltd Corcept Therapeutics Inc Eli Lilly and Company Embera NeuroTherapeutics Inc Immodulon Therapeutics Ltd Intra-Cellular Therapies Inc Marinus Pharmaceuticals Inc Neuralstem Inc NeuroNascent Inc Omeros Corp Otsuka Holdings Co Ltd Pragma Therapeutics SAS Synchroneuron Inc Tonix Pharmaceuticals Holding Corp Post-Traumatic Stress Disorder (PTSD) - Drug Profiles (metyrapone + oxazepam) - Drug Profile Product Description Mechanism Of Action R&D Progress acamprosate calcium SR - Drug Profile Product Description Mechanism Of Action R&D Progress ADX-71743 - Drug Profile Product Description Mechanism Of Action R&D Progress AM-3506 - Drug Profile Product Description Mechanism Of Action R&D Progress BNC-210 - Drug Profile Product Description Mechanism Of Action R&D Progress brexpiprazole - Drug Profile Product Description Mechanism Of Action R&D Progress CERC-501 - Drug Profile Product Description Mechanism Of Action R&D Progress CPP-115 - Drug Profile Product Description Mechanism Of Action R&D Progress CTDP-003 - Drug Profile Product Description Mechanism Of Action R&D Progress D-473 - Drug Profile Product Description Mechanism Of Action R&D Progress ganaxolone - Drug Profile Product Description Mechanism Of Action R&D Progress IC-87201 - Drug Profile Product Description Mechanism Of Action R&D Progress IMM-201 - Drug Profile Product Description Mechanism Of Action R&D Progress INV-107 - Drug Profile Product Description Mechanism Of Action R&D Progress KDAC-0001 - Drug Profile Product Description Mechanism Of Action R&D Progress lumateperone tosylate - Drug Profile Product Description Mechanism Of Action R&D Progress midomafetamine - Drug Profile Product Description Mechanism Of Action R&D Progress modafinil - Drug Profile Product Description Mechanism Of Action R&D Progress NNI-351 - Drug Profile Product Description Mechanism Of Action R&D Progress NSI-189 - Drug Profile Product Description Mechanism Of Action R&D Progress PGT-117 - Drug Profile Product Description Mechanism Of Action R&D Progress Rycal - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize EP1 for Post-Traumatic Stress Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize Nociceptin Receptor for Post Traumatic Stress Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress SRX-246 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptide to Target NPSR for Anxiety Disorder - Drug Profile Product Description Mechanism Of Action R&D Progress TNX-102 - Drug Profile Product Description Mechanism Of Action R&D Progress TNX-601 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for CNS Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress ZL-006 - Drug Profile Product Description Mechanism Of Action R&D Progress Post-Traumatic Stress Disorder (PTSD) - Dormant Projects Post-Traumatic Stress Disorder (PTSD) - Discontinued Products Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones Featured News & Press Releases Jun 16, 2017: Tonix Pharmaceuticals to Present at the 2017 BIO International Convention Jun 15, 2017: Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data Jun 15, 2017: Tonix Pharmaceuticals Participated in the Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets Summit Sponsored by U.S. Department of Defense Jun 12, 2017: Tonix Pharmaceuticals to Present an Update of FDA Designated Breakthrough Therapy-TNX-102 SL for PTSD at the 2017 Marcum MicroCap Conference May 30, 2017: Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study May 24, 2017: Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting May 22, 2017: Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD May 20, 2017: Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention May 02, 2017: Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use Apr 11, 2017: Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder Mar 29, 2017: Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference Mar 28, 2017: Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL Mar 15, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer's 27th Annual Healthcare Conference Mar 14, 2017: Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL Mar 07, 2017: Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cerecor Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co Ltd, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics SAS, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2017 Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
